Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.

[1]  E. Beierle,et al.  FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma , 2013, Clinical & Experimental Metastasis.

[2]  S. Ramalingam,et al.  Hsp90 inhibitors. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  M. Flentje,et al.  Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity. , 2012, Translational oncology.

[4]  E. Wattel,et al.  Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase , 2012, Oncotarget.

[5]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[6]  M. Flentje,et al.  Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia , 2012, Cancer biology & therapy.

[7]  M. Murata,et al.  Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B. , 2011, Rheumatology.

[8]  S. Ponnambalam,et al.  Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. , 2011, Biochemical and biophysical research communications.

[9]  N. Cordes,et al.  The Role of the Focal Adhesion Protein PINCH1 for the Radiosensitivity of Adhesion and Suspension Cell Cultures , 2010, PloS one.

[10]  M. Jensen,et al.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction , 2010, British Journal of Cancer.

[11]  J. Brueggen,et al.  Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800 , 2010, Molecular Cancer Therapeutics.

[12]  M. Jensen,et al.  Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. , 2010, Current opinion in drug discovery & development.

[13]  Michael C. Ostrowski,et al.  Erk1 and Erk2 Regulate Endothelial Cell Proliferation and Migration during Mouse Embryonic Angiogenesis , 2009, PloS one.

[14]  E. Gulbins,et al.  Induction of Membrane Ceramides: A Novel Strategy to Interfere with T Lymphocyte Cytoskeletal Reorganisation in Viral Immunosuppression , 2009, PLoS pathogens.

[15]  X. Barril,et al.  Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of Medicinal Chemistry.

[16]  J. Bai,et al.  Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion , 2009, British Journal of Cancer.

[17]  M. Taniwaki,et al.  A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. , 2009, Cancer letters.

[18]  Kazunori Kihara,et al.  Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. , 2009, Anticancer research.

[19]  A. Robles,et al.  HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair , 2008, Molecular Cancer Therapeutics.

[20]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[21]  Richard P. Hill,et al.  Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability , 2008, Nature Reviews Cancer.

[22]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[23]  Jonathan M Lee,et al.  Geldanamycin Anisimycins Activate Rho and Stimulate Rho- and ROCK-Dependent Actin Stress Fiber Formation , 2007, Molecular Cancer Research.

[24]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[25]  A. Wiestner,et al.  Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines , 2006, Clinical Cancer Research.

[26]  Huifang M. Zhang,et al.  Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kappaB signaling in intestinal epithelial cells. , 2006, American journal of physiology. Cell physiology.

[27]  中村雅阳,et al.  Novel hsp90 inhibitors , 2006 .

[28]  T. Tsuruo,et al.  Stabilization of integrin-linked kinase by binding to Hsp90. , 2005, Biochemical and biophysical research communications.

[29]  Ken Jacobson,et al.  MAP kinases and cell migration , 2004, Journal of Cell Science.

[30]  L. Neckers,et al.  Heat shock protein 90 , 2003, Current opinion in oncology.

[31]  A. Hall,et al.  Rho GTPases in cell biology , 2002, Nature.

[32]  J. Kuratsu,et al.  Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK). , 2002, Cancer Letters.

[33]  D. Picard,et al.  Heat-shock protein 90, a chaperone for folding and regulation , 2002, Cellular and Molecular Life Sciences CMLS.

[34]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[35]  S. Dedhar,et al.  The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9) , 2000, Oncogene.

[36]  S. Hanks,et al.  Anti-apoptotic Role of Focal Adhesion Kinase (FAK): Induction of Inhibitor-of-Apoptosis Proteins and Apoptosis Suppression by the Overexpression of FAK in a Human Leukemic Cell Line, HL-60 , 2000 .

[37]  S. Hanks,et al.  Anti-apoptotic Role of Focal Adhesion Kinase (FAK) , 2000, The Journal of Biological Chemistry.

[38]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[39]  B. van de Water,et al.  Dephosphorylation of Focal Adhesion Kinase (FAK) and Loss of Focal Contacts Precede Caspase-mediated Cleavage of FAK during Apoptosis in Renal Epithelial Cells* , 1999, The Journal of Biological Chemistry.

[40]  D. Schlaepfer,et al.  Signaling through focal adhesion kinase. , 1999, Progress in biophysics and molecular biology.

[41]  K. Kaibuchi,et al.  Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.

[42]  E. Ruoslahti,et al.  Control of adhesion-dependent cell survival by focal adhesion kinase , 1996, The Journal of cell biology.

[43]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis. , 1995, The American surgeon.

[44]  G. Johnson,et al.  Gα12 and Gα13 Stimulate Rho-dependent Stress Fiber Formation and Focal Adhesion Assembly (*) , 1995, The Journal of Biological Chemistry.

[45]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.

[46]  Aftab Taiyab,et al.  HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion. , 2011, Biochimica et biophysica acta.

[47]  M. Egorin,et al.  Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts , 2004, Cancer Chemotherapy and Pharmacology.

[48]  L. Neckers,et al.  The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. , 1999, Molecular genetics and metabolism.